UK NICE guidance says breast cancer drug Perjeta not value for money
The UK’s National Health Service (NHS) is to be advised that it should not routinely provide Swiss drug major Roche’s (ROG: SIX) Perjeta (pertuzumab) as a treatment for a type of advanced breast cancer.
Draft guidance issued today (August 6) by the drugs watchdog the National Institute for Health and Care Excellence (NICE) does not recommend its use because clinical trial data could not predict for how long the drug might extend people’s lives yet it costs much more than current NHS treatments. The NICE has now opened a consultation on this draft guidance with organizations including charities, patient groups, NHS trusts and drug manufacturers being asked for their views.
Perjeta could become seventh such cancer drug to be rejected by the NICE since 2011
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze